









Markets
/
Stocks
/
nasdaq-immx
/

Immix Biopharma Inc

IMMX

View Detailed Chart

2.650USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

73.81MMarket Cap

LossP/E TTM



Immix Biopharma Inc

2.650

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

-2.57%

5 Days

-2.21%

1 Month

+3.92%

6 Months

+35.90%

Year to Date

+20.45%

1 Year

+23.83%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 1 analysts

BUY

Current Rating

7.000

Target Price

164.15%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Immix Biopharma Inc

IMMX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(6)

Neutral(2)

Buy(3)

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.081

Neutral

RSI(14)

49.640

Neutral

STOCH(KDJ)(9,3,3)

9.976

Oversold

ATR(14)

0.220

Low Volatility

CCI(14)

-110.157

Sell

Williams %R

96.491

Oversold

TRIX(12,20)

0.601

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.708

Sell

MA10

2.778

Sell

MA20

2.783

Sell

MA50

2.473

Buy

MA100

2.139

Buy

MA200

2.023

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

Ticker SymbolIMMX

CompanyImmix Biopharma Inc

CEODr. Ilya Rachman, M.D., Ph.D.

Websitehttps://immixbio.com/